New cocktail of drugs takes on tough breast cancer
NCT ID NCT06027268
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing a combination of four drugs—trilaciclib, pembrolizumab, gemcitabine, and carboplatin—in people with advanced triple-negative breast cancer that cannot be removed by surgery or has spread. The study aims to see how well the treatment works and how safe it is. Thirty-six participants are being enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trilaciclib, pembrolizumab, gemcitabine, and carboplatin
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced triple-negative breast cancer, potentially slowing tumor growth.
What could go wrong
This is a small, early-phase trial (36 participants) with no control group, so results may not be definitive. The combination of drugs may cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States